Yuekang Pharmaceutical: Subsidiary YKYY029 Injection Receives Approval for Clinical Trial.

Yuekang Pharmaceutical announced that its subsidiaries Yuekang Innovations and Hangzhou Tianlong have been granted approval by the National Medical Products Administration to conduct Phase I clinical trials for YKYY029 injection for the treatment of hypertension. YKYY029 injection is a small interfering ribonucleic acid drug targeting the AGT gene, independently developed by Yuekang Innovations and Hangzhou Tianlong. It has a new sequence and uses a new modified template of siRNA sequence developed by the company, with global exclusive rights.